Condition
Solid Tumor, Adult Lymphoma
Total Trials
2
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 1 (2)
Trial Status
Not Yet Recruiting1
Recruiting1
Clinical Trials (2)
Showing 2 of 2 trials
NCT05358379Phase 1RecruitingPrimary
A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma
NCT05788107Phase 1Not Yet RecruitingPrimary
Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX51 in Patients With Solid Tumor or Lymphoma
Showing all 2 trials